Identification of enzymes responsible for rifalazil metabolism in human liver microsomes

References

• ALDRIDGE, W. N., 1953, Serum esterases : two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochemical Journal, 53, 110–117.
   PubMed Web of Science ®Google Scholar
• BATTAGLIA, R., PIANEZZOLA, E., SALGAROLLO, G., ZINI, G. and STROLIN-BENEDETTI, M., 1990, Absorption, disposition and preliminary metabolic pathway of "C-rifabutin in animals and man. Journal of Antimicrobial Chemotherapy, 26, 813–822.
   Google Scholar
• BERMUDEZ, L. E., KOLONOSKI, P., YOUNG, L. S. and INDERLIED, C. B., 1994, Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterizon avium in beige mouse model of disseminated infection. Antimicrobial Agents and Chemotherapy, 38, 1844–1848.
   Web of Science ®Google Scholar
• COCCHIARA, G., STROLIN BENEDETTI, M., VICARIO, G. P., BALLABIO, M., GIOIA, B., VIOGLIO, S. and VIGEVANI, A., 1989, Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica, 19, 769–780.
   PubMed Web of Science ®Google Scholar
• Fuji', K., Tsuji, A., MIYAZAKI, S., YAMAGUCHI, K. and GOTO, S., 1994, In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrobial Agents and Chemotherapy, 38, 1118–1122.
   Google Scholar
• HIRATA, T., SAITO, H., TOMIOKA, H., SATO, K., Jinoi, J., HOSOE, K. and HIDATA, T., 1995, In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 39, 2295–2303.
   PubMed Web of Science ®Google Scholar
• HOSOE, K., MAE, T., KONISHI, E., Fuji', K., YAMASHITA, K., YAMANE, T., HIDAKA, T. and OHASI, T., 1996a, Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrobial Agents and Chemotherapy, 40, 2749–2755.
   Google Scholar
• HOSOE, K., MAE, T., YAMASHITA, K., Fuji', K., YAMANE, T., HIDAKA, T. and OHASI, T., 1996b, Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog. Xenobiotica, 26, 321–332.
   Google Scholar
• IATSIMIRSKAIA, E., TULEBAEV, S., STOROZHUK, E., UTKIN, I., SMITH, D., GERBER, N. and KOUDRIAKOVA, T., 1997, Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clinical Pharmacology and Therapeutics, 61, 554–562.
   PubMed Web of Science ®Google Scholar
• INABA, T., FISCHER, N. E., RIDDICK, D. S., STEWART, D. J. and HIDAKA, T., 1997, HIV protease inhibitors, saquinavir, indinavir and ritonavir : inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicology Letters, 93, 215–219.
   PubMed Web of Science ®Google Scholar
• INDERLIED, C. B., BARBARA-BURNHAM, L., Wu, M., YOUNG, L. and BERMUDEZ, L. E., 1994, Activity of the benzoxazinorifamycin KRM-1648 against the Mycobacterium avium complex in vitro and in macrophages. Antimicrobial Agents and Chemotherapy, 38, 1838–1843.
   Google Scholar
• JAmis-Dow, C. A., KATKI, A. G., COLLINS, J. M. and KLECKER, R. W., 1997, Rifampicin and rifabutin and their metabolism by human liver esterases. Xenobiotica, 27, 1015–1024.
   Google Scholar
• KELLY, B. P., FURNEY, S. K., JESSEN, M. T. and ORME, I. M., 1996, Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 40, 2809–2812.
   PubMed Web of Science ®Google Scholar
• KLEMENS, S. P., GROSSI, M. A. and CYNAMON, M. H., 1994, Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy, 38, 2245–2248.
   PubMed Web of Science ®Google Scholar
• LUNA-HERRERA, J., REDDY, M. V. and GANGADHARAM, P. R. J., 1995, In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy, 39, 4401/4.
   Google Scholar
• MAE, T., HOSOE, K., Fuji', K., YAMASHITA, K., YAMANE, T., HIDAKA, T. and OHASHI, T., 1996, In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. Xenobiotka, 26, 793–802.
   Google Scholar
• MAE, T., HOSOE, K., YAMAMOTO, T., HIDAKA, T., OHASHI, T., KLEEMAN, J. M. and ADAMS, P. E., 1998, Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xenobiotica, 28, 759–766.
   PubMed Web of Science ®Google Scholar
• MAE, T., KONISHI, E., HOSOE, K. and HIDAKA, T., 1999, Isolation and identification of major metabolites of rifalazil in mouse and human. Xenobiotka, 29, 1073–1087.
   PubMed Web of Science ®Google Scholar
• MOGHAZEH, S. L., PAN, X., ARAIN, T., STOVER, C. K., MUSSER, J. M. and KREISWIRTH, B. N., 1996, Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrobial Agents and Chemotherapy, 40, 2655–2657.
   PubMed Web of Science ®Google Scholar
• MOR, N., SIMON, B. and HEIFETS, L., 1996, Bacteriostatic and bactericidal activities of benzoxazino-rifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrobial Agents and Chemotherapy, 40, 1482–1485.
   PubMed Web of Science ®Google Scholar
• PARKINSON, A., 1996, Biotransformation of xenobiotics. In C. D. Klaassen (eds), Casaret & Doull's Toxicology: The Basic Science of Poisons, 5th edn (New York: McGraw-Hill), pp. 113–186.
   Google Scholar
• REDDY, M. V., LUNA-HERRERA, J., DANELUZZI, D. and GANGADHARAM, P. R., 1996, Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tubercle and Lung Disease, 77,154–159.
   Google Scholar
• REITH, K., KEUNG, A., TOREN, P. C., CHENG, L., ELLER, M. G. and WEIR, S. J., 1998, Disposition and metabolism of "C-rifapentine in healthy volunteers. Drug Metabolism and Disposition, 26, 732–738.
   PubMed Web of Science ®Google Scholar
• SAITO, H., TOMIOKA, H., SATO, K., EMORI, M., YAMANE, T., YAMASHITA, K., HOSOE, K. and HIDAKA, T., 1991, In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrobial Agents and Chemotherapy, 35, 542–547.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SUMIDA, A., KINOSHITA, K., FUKUDA, T., MATSUDA, H., YAMAMOTO, I., INABA, T. and AZUMA, J., 1999, Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochemical and Biophysical Research Communications, 262, 499–503.
   PubMed Web of Science ®Google Scholar
• TOMIOKA, H., SAITO, H., Fum, K., SATO, K. and HIDAKA, T., 1993, In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex determined by the radiometric method. Antimicrobial Agents and Chemotherapy, 37, 67–70.
   PubMed Web of Science ®Google Scholar
• TOMIOKA, H., SAITO, H., SATO, K., YAMANE, T., YAMASHITA, K., HOSOE, K., Fuji', K. and HIDAKA, T., 1992, Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy, 36, 387–393.
   Google Scholar
• TRAPNELL, C. B., JAmis-DOW, C., KLECKER, R. W. and COLLINS, J. M., 1997, Metabolism rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrobial Agents and Chemotherapy, 41, 924–926.
   Google Scholar
• UTKIN, I., KOUDRIAKOVA, T., THOMPSON, T., COTTRELL, C., IATSIMIRSKAIA, E., BARRY, J., VOUROS, P. and GERBER, N., 1997, Isolation and identification of major urinary metabolites of rifabutin in rats and humans. Drug Metabolism and Disposition, 25, 963–969.
   PubMed Web of Science ®Google Scholar
• VIGEVANI, A., BALLABIO, M., GIOIA, B., MARSILI, L., VIOGLIO, S. and FRANCESCHI, G., 1985, Identification of urinary metabolites of rifamycin LM 427 in man. Journal of Antibiotics, 38, 1799–1802.
   PubMed Web of Science ®Google Scholar
• WILLIAMS, F. M., 1985, Clinical significance of esterases in man. Clinical Pharmacokinetks, 10,392–403.
   PubMed Web of Science ®Google Scholar
• YAMANE, T., HASHIZUME, T., YAMASHITA, K., KONISHI, E., HOSOE, K., HIDATA, T., WATANABE, K., KAWAHARADA, H., YAMAMOTO, T. and KUZE, F., 1993, Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives. Chemical and Pharmaceutical Bulletin, 41, 148–155.
   PubMed Web of Science ®Google Scholar
• YANG, B., KOGA, H., OHNO, H., OGAWA, K., FUKUDA, M., HIRAKATA, Y., MAESAKI, S., TOMONO, K., TASHIRO, T. and KOHNO, S., 1998, Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterizon tuberculosis. Journal of Antimicrobial Chemotherapy, 42, 621–628.
   PubMed Web of Science ®Google Scholar